Host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non-small cell lung cancer patients
To our knowledge, this is the first study to depict the predictive role of the host and bacterial urine proteome in anti-PD1-treated advanced NSCLC.
Authors
- Péter Revisnyei (ORCID: https://orcid.org/0000-0002-9459-8335)
- Edit Dulka
- Anton Iliuk (ORCID: https://orcid.org/0000-0002-2914-1363)
- Dávid Dóra (ORCID: https://orcid.org/0000-0002-2975-5701)
- Alija Pašíć (ORCID: https://orcid.org/0000-0001-6346-496X)
- Zoltán Lohinai (ORCID: https://orcid.org/0000-0002-6442-9530)
- Gabriella Gálffy (ORCID: https://orcid.org/0000-0001-7255-035X)
- Glen J. Weiss (ORCID: https://orcid.org/0000-0002-6067-597X)
- Sára Szincsak
- Anna Mihucz
- Brigitta Roskó
Institutions
- Semmelweis University (HU)
- University of Massachusetts Chan Medical School (US)
- Budapest University of Technology and Economics (HU)
- Magyar Madártani és Természetvédelmi Egyesület (HU)
- Tymora Analytical Operations (United States) (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-14
- DOI
- https://doi.org/10.3389/fimmu.2025.1543817
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14